Beta Bionics (BBNX) stock

Diabetes medical device , market cap $842M

Diabetes medical device

Worth $842M

$16.52

-2.54%

As of Tuesday's close · Live for Pro members at the open

Why is BBNX down?

Down 23% from Oct 27 to Nov 10.

Beta Bionics fell 23% from Oct 27 to Nov 10. 17 points of it came on Oct 28, the session after its Oct 27 results.

Sources: Price history, Nov 10, 2026; SEC filing, Oct 27, 2026

Tell me next time BBNX moves

Free account, no card. An optional alert when BBNX moves or its score changes.

Or see it live, free until Thursday morning. No account.

1 more reason, free with an account →2 more reasons why BBNX fell 23% since Oct 27, from its filings, with the other side, the timeline, and its peers, for Pro members.

Quality Score

Below Average

In its industry

#51of 84

Medical Devices

Checks firing

3of 14

Choppy

From 52-week high

-49.5%

under its best in a year

BBNX's Quality Score fell 1 point on Tue, Nov 10, to 4. It closed away from its high of the day (2 chart checks stopped).

See BBNX's 14 chart checksSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Key facts on BBNX

Key facts on BBNX
Holding it back	Moves 9.1% a day with no profit behind it
Latest filing	10-Q, Oct 27 Filed its quarterly report (10-Q) for the quarter to Sep 30, 2026

1 more reason behind BBNX's 4, free with an account →3 more reasons behind BBNX's 4, for Pro members.

BBNX in the news

Wed Oct 28Beta Bionics reported quarterly revenue of $35.5 million and a diluted loss of $0.52 a share SEC, 4:04 PM ET BBNX closed −16.5% that day.

What's next

Wed Nov 11: Stifel Healthcare Conference 2026Investor conference · date confirmed.

3 more dates ahead: conferences, for Pro members.

BBNX catalysts

Coming up

After its last 4 reports it closed -6.4% on average, higher 0 of 4 times.

8 past catalysts since 2025, with sizes and sources, for Pro members.

Why BBNX scores 4

Below Averagefor quality, not price, 3 of 14 chart checks firingWhat the Quality Score means

+3Chart checks 3 of 14 firing right now, one point each
+3Growth sales up 44% on the year, gross margin up 4.1 pointsSales and margins against a year earlier: up to +3 for fast growth and widening margins, down to -2 when both shrink.

Run-up adds
Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
Cash flow subtracts-1 when free cash flow over the last four quarters is negative.

No effect today: Long-term trend, Size, Dilution, Persistence, News, and Insider trades.

What every line is worth, and the reason behind it, on BBNX and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 10:45 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

How BBNX ranks in Medical Devices

BBNX is #51 of 84 by Quality Score.

How BBNX ranks in Medical Devices
Rank	Stock	Checks	Quality Score
1	DCTHDelcath Systems	7/14	22
2	EWEdwards Lifesciences	7/14	19
3	WSTWest Pharmaceutical Services	7/14	18
	AXGNAxogen		Open for its score
	BAXBaxter International		Open for its score
	BDXBecton, Dickinson		Open for its score
	BLCOBausch + Lomb		Open for its score
51	BBNXBeta Bionics	3/14	4

When does BBNX report earnings, and what happens after?

Expected to report Tue Feb 16, after the close (in 98 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What BBNX reported on Oct 27, 2026

The quarter

Sales of $35.5M, 30% more than a year ago; a loss of $0.52 a share, from $0.33.

“Revenue guidance reflects a potential revenue deferral impact of up to $8.5 million in the fourth quarter of 2026 as new prospective iLet users could choose to await the launch of Mint.”

The quarter that ended Sep 30, from the company's press release

The press release The filing on EDGAR

Where the sales came from

BBNX's results filing gives no sales by line in a table we read.

The outlook

The outlook the company gave, by period
Measure	Figure
2026 Full Year
Total revenue	$124M to $126Mraised

Figures as filed (SEC filing, Oct 27)

1 more outlook line, for Pro members.

In the company's words

“During the full year 2027, the Company expects Mint to recapture any revenue lost in the fourth quarter of 2026.”

From its results filing (SEC filing · Oct 27)

The numbers

Market value: $842M; today
Sales: $127M; up 43.7% on the year
Free cash flow: -$66M; last 12 months

3 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on BBNX: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 4

-2.6%-0.6%-5.9%-16.6%

Feb 17Apr 21Jul 29Oct 27

Reported	When	Gap	Reaction	5 days
Oct 27, 2026After close	After close	-12.5%	-16.6%	-29.4%
Jul 29, 2026After close	After close	+5.3%	-5.9%	-8.3%
Apr 21, 2026After close	After close	+5.6%	-0.6%	-17.9%
Feb 17, 2026After close	After close	-7.7%	-2.6%	-4.2%

BBNX closed higher after 0 of its last 4 reports.

BBNX sales and profit by year

Sales and profit by year

Sales grew every year from 2023 to 2025, to $100M. It lost money in each of the three years.

BBNX has 3 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on BBNX, and all 14 on every stock.Get in free →

BBNX RSI today: 45.4, below its 50-day, above its 200-day

Not scored

RSI 45.4, MACD below signal, below its 50-day, above its 200-day. Not scored.13 readings

The deep dive on BBNX

What it does and how it makes money4 findingsAn operating loss of $71.7M in fiscal 2025, on $100M of sales.Annual report, filed Feb 24, 2026"Assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees, as applicable, our owned or licensed issued U.S. patents expire between 2026 and 2042." (10-K for fiscal 2025)SEC filing · Feb 24, 2026
Where it stands5 findingsFor Pro members5 findings on where BBNX stands: its cash, debt, and share count, for Pro members
What changed in its filings7 findings"In September 2026, a purported stockholder of the Company filed a securities class action against the Company and certain of its executive officers in the United States District Court for the Central District of California, captioned Holtzman vs. Beta Bionics, Inc. et al. , Case No. 8:26-cv-2612-JWH (KESx)." (10-Q for the quarter to Sep 30, 2026)SEC filing · Oct 27, 2026A new heading in its "Risk Factors" this year: "International trade policies, including tariffs, sanctions and trade barriers may adversely affect our business, financial condition, results of operations and prospects." (10-K for fiscal 2025; not in fiscal 2024's)SEC filing · Feb 24, 2026, against the one of Mar 25, 2025One distributor made up 14% of its revenue in fiscal 2025, up from 13% in fiscal 2024; another made up 13%, down from 18% in fiscal 2024.SEC filing · Feb 24, 2026Backlog rose 54% in a year, to $2.00M on Sep 30, 2026 from $1.30M: sales under contract, not yet delivered.Filed figures, Sep 30, 2026
Who holds and trades it3 findingsFor Pro members3 findings on who holds and trades BBNX, for Pro members

13 more findings on BBNX, each with its source, for Pro members.

BBNX share count over time

Shares: 6.7% more than a year ago (to Sep 30).

Shares of BBNX outstanding, as filed
Shares outstanding	As of
54.4M	Oct 26, 2026
45M	Jul 27, 2026
44.6M	Apr 16, 2026
44.4M	Feb 20, 2026

Offerings, shelves, and splits of BBNX, from its filings
From its filings	Filed
Raised $132M in a sale of shares, about 16% of its market value	Sep 17, 2026

BBNX insider trades

5 insiders sold $1.2M across 12 filings in the last 6 months. No open-⁠market buys on record. The newest:

SellMark Hopman$13KChief Commercial Officerat $17.35 on Oct 14, filed Oct 16

SellMark HopmanChief Commercial Officer$13Kat $17.35 on Oct 14, filed Oct 16

All 12 insider filings on BBNX from the last six months, for Pro members.

BBNX's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Sean SaintPresident & CEO · 4 trades
Stephen FeiderChief Financial Officer · 7 trades
Mark HopmanChief Commercial Officer · 14 trades
Mike MensingerChief Product Officer · 7 trades
Steven Jon RussellChief Medical Officer · 3 trades
Christy JonesDirector · 4 trades
Adam LezackDirector · 3 trades
Maria PalasisDirector · 1 trade

3 more officers and directors file at BBNX.

See insider trades by person

Which ETFs hold BBNX?

In ETFs: BBNX is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Beta Bionics

Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.

423 employeesIrvine, CAbetabionics.com

What Beta Bionics says it competes with

“The medical device industry is intensely competitive, subject to rapid change, and highly sensitive to the introduction of new products, treatment techniques or technologies, and other market activities of industry participants.”

From its annual report, SEC filing · Feb 24, 2026

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on BBNX and every other stock.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would turn BBNX's score around: 6 things
3 more filings explained, a plain line each
Real-⁠time prices, no delay

BreakawayOct 16Mark Hopman sold BBNX$13K at $17.35, filed Oct 16

Alerts are optional.

See BBNX's 14 chart checks

See it live, free until Thursday morning. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 10, 2026: BBNX's Quality Score is 4 (Below Average), #51 of 84 in Medical Devices. Insiders sold $1.2M in the last 6 months (Form 4).

What does BBNX's Quality Score say?

BBNX scores 4 today, which Breakaway calls Below Average. It is #51 of 84 in Medical Devices by Quality Score, with 3 of 14 chart checks firing. Down 23% from Oct 27 to Nov 10. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is BBNX's Quality Score?

BBNX scores 4 today, which Breakaway calls Below Average (0 to 5). That is #51 of 84 in Medical Devices by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind BBNX's 4.

Are insiders buying BBNX?

5 insiders sold $1.2M across 12 filings in the last 6 months. No open-⁠market buys on record. The newest is Mark Hopman, Chief Commercial Officer, who sold $13K on Oct 14. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.